Diabetes in Japan: A review of disease burden and approaches to treatment

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 8, 2009, Pages 705-716

  Neville, Susan E ^a   Boye, Kristina S ^b   Montgomery, William S ^c   Iwamoto, Kazuya ^b   Okamura, Masato ^b   Hayes, Risa P ^b  

^a TOTAL   (France)

^b ELI LILLY AND COMPANY   (United States)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Health economics; Japan; Treatment; Type 1 diabetes; Type 2 diabetes; epidemiology

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; VOGLIBOSE;

BODY MASS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; GENETICS; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; JAPAN; LENGTH OF STAY; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS;

COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; JAPAN; PRACTICE GUIDELINES AS TOPIC;

EID: 73349083380     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1012     Document Type: Review

References (75)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Takasu N, Yogi H, Takara M, et al. Influence ofmotorization and supermarket-proliferation on the prevalence of type 2 diabetes in the inhabitants of a small town on Okinawa, Japan. Intern Med 2007; 46: 1899-1904.
3. Statistical Handbook Japan. Statistics Bureau: Japan, 2007.
4. Abe A. Social Security in Japan. National Institute of Population and Social Security Research, International Cooperation and Research Division: Tokyo, Japan, 2007.
5. Nomura H, Nakayama T. The Japanese healthcare system. BMJ 2005; 331: 648-649.
6. Imai Y. Health care reform in Japan, Economics Department Working Papers. OECD: Paris, France, 2002.
7. Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan. Nat Med 2006; 12: 73-74.
8. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18(Suppl 3): S9-13.
9. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes. Practical Targets and Treatments (4th edn). International Diabetes Institute: Melbourne, Australia, 2005.
10. Kawasaki E, Eguchi K. Is Type 1 diabetes in the Japanese population the same as among Caucasians. Ann N Y Acad Sci 2004; 1037: 96-103.
11. Ikegami H, Fujisawa T, Kawabata Y, Noso S, Ogihara T. Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. Ann N Y Acad Sci 2006; 1079: 51-59.
12. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 26: 2345-2352.
13. Mackay J, Mensah G. Atlas of Heart Disease and Stroke, Order no. 11500601. World Health Organization: Geneva, Switzerland, 2004. ISBN 92 4 156276 5.
14. Moon L, Moise P, Jacobzone S, Group A-SE. Stroke Care in OECD Countries: A Comparison of Treatment, Costs and Outcomes in 17 Countries. OECD: Paris, France, 2003.
15. Sone H, Mizuno S, Fujii H, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005; 28: 1463-1471.
16. Kiyohara Y. Cerebrovascular disease and diabetes mellitus [Japanese]. Nippon Rinsho 2007; 65: 763-769.
17. Sugimori H, Miyakawa M, Yoshida K, et al. Health risk assessment for diabetes mellitus based on longitudinal analysis of MHTS database. J Med Syst 1998; 22: 27-32.
18. Yamada M, Wong FL, Kodama K, Sasaki H, Shimaoka K, Yamakido M. Longitudinal trends in total serum cholesterol levels in a Japanese cohort, 1958-1986. J Clin Epidemiol 1997; 50: 425-434.
19. HorikoshiM, Hara K, Ito C, et al. Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia 2007; 50: 2461-2466.
20. Omori S, Tanaka Y, Takahashi A, et al. Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes 2008; 57: 791-795.
21. Horikawa Y, Miyake K, Yasuda K, et al. Replication of genomewide association studies of type 2 diabetes susceptibility in Japan. J Clin Endocrinol Metab 2008; 93: 3136-3141.
22. Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40: 1092-1097.
23. Kawasaki E, Eguchi K. Current aspects on the clinical immunology and genetics of autoimmune diabetes in Japan. Diabetes Res Clin Pract 2007; 77(Suppl 1): S104-S109.
24. Kawasaki E, MatsuuraN, Eguchi K. Type 1 diabetes in Japan. Diabetologia 2006; 49: 828-836.
25. Matsuura N, Fukuda K, Okuno A, et al. Descriptive epidemiology of IDDM in Hokkaido, Japan: the Childhood IDDM Hokkaido Registry. Diabetes Care 1998; 21: 1632-1636.
26. Japan IDDM Epidemiology Study Group. Lack of regional variation in IDDM risk in Japan. Diabetes Care 1993; 16: 796-800.
27. World Health Organization Western Pacific Region. Plan of Action for the Western Pacific Declaration on Diabetes 2000-2005. Manila: International Diabetes Foundation - Western Pacific Regional Office, 2001.
28. National Diabetes Survey [Japanese]. Tokyo: Ministry of Health, Labour and Welfare, 1998 and 2003.
29. Igari Y, Nakano H, Oba K. Epidemiology of elderly diabetes mellitus in Japan [Japanese]. Nippon Rinsho 2006; 64: 12-18.
30. Sekikawa A, Eguchi H, Tominaga M, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata Diabetes Study. J Diabetes Complications 2000; 14: 78-83.
31. Nakanishi S, Okubo M, Yoneda M, Jitsuiki K, Yamane K, Kohno N. A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother 2004; 58: 571-577.
32. Urakami T, Owada M, Kitagawa T. Recent trend toward decrease in the incidence of childhood type 2 diabetes in Tokyo. Diabetes Care 2006; 29: 2176-2177.
33. Urakami T, Morimoto S, Nitadori Y, Harada K, Owada M, Kitagawa T. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res 2007; 61: 141-145.
34. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 2005; 28: 1876-1881.
35. Sugihara S, Sasaki N, Amemiya S, Kohno H, Tanaka T, MatsuuraN. Analysis of weight at birth and at diagnosis of childhood-onset type 2 diabetes mellitus in Japan. Pediatr Diabetes 2008; 9: 285-290.
36. Otabe S, Nakayama H, Fukutani T, et al. Clinical and genetic features of childhood-onset Type 2 diabetes in Japan. Acta Diabetol 2007; 44: 181-185.
37. Kamae I, Kasuga M. Medical economics of diabetes - consideration of its background and significance [Japanese]. Medical ASAHI 2003; 68-72.
38. Takeda A. The policy for diabetes of local government [Japanese]. Nippon Rinsho 2002; 60(Suppl 10): 608-612.
39. Hisashige A, Katayama T, Mikasa H. Issues of disease management strategy for diabetes mellitus in Japan. Annual Meeting of the International Society of Technology Assessment in Health Care, 2001.
40. Miwa S, Kawamori R. Treatment policy for elderly diabetic patients in preparation for the super-aged society [Japanese]. Nippon Rinsho 2006; 64: 7-11.
41. Oishi M, Yokoyama H, Abe N, et al. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4). Diabet Med 2007; 24: 1149-1155.
42. Nishimura Y, Chikamoto Y, Arima H. Association between lifestyle-disease diagnosis or risk status and medical care costs in a Japanese corporation. Am J Health Promot 2005; 19: 249-254.
43. Sakamaki H, Kitazawa T, Hasegawa T. Relationship between risks for lifestyle-related diseases and medical expenses after 10 years ofmetabolic syndrome. Value in Health, ISPOR: Dublin, Ireland, 2007; A367-A368.
44. Oishi M, Kakihara H. Study of medical cost for diabetes outpatients [Japanese]. Tonyobyo (Diabetes, the journal of Japan Diabetic Society) 1999; 42: 909-915.
45. Kakihara H. Theoretical drug price model using pharmacoeconomic analysis methodology - relating to the development of new diabetes drugs [Japanese]. Kyofuidai shi (the journal of Kyoto Prefectural University of Medicine) 1994; 103: 475-487.
46. Suzuki Y. Analysis of medical cost of complications in diabetes mellitus [Japanese]. Nippon Koshu Eisei Zasshi 2005; 52: 652-663.
47. Uchigata Y, Origasa H, Sakamaki H, Iwamoto Y. Health economic analysis for diabetic mellitus. Examination of the relationship between diabetic complications and medical expenditure [Japanese]. J Jpn Diabetes Soc 1999; 42: 743-750.
48. Inada O, Nishimura S, Seino Y, Tsuda K. Cost of medical care of type 2 diabetes mellitus outpatients-effect of healthcare reform on the diabetes clinic [Japanese]. J Jpn Diab Soc 2005; 48: 677-684.
49. Anzai M. Statisitic data of diabetes care in Osaka prefecture [Japanese]. Shakai Hoken Junpo 2006; 2300: 10-17.
50. Inada O, Nishimura S, Matsushima M, Seino Y, Tsuda K. The direct medical costs and the quality of life in patients with artificial dialysis and type 2 diabetes [Japanese]. J Jpn Diab Soc 2007; 50: 1-8.
51. Matsushima M, Tajima N, Agata T, Yokoyama J, Ikeda Y, Isogai Y. Social and economic impact on youth-onset diabetes in Japan. Diabetes Care 1993; 16: 824-827.
52. Babazono A, Miyazaki M, Imatoh T, et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. Int J Technol Assess Health Care 2005; 21: 228-233.
53. Babazono A, Miyazaki M, Une H, Yamamoto E, Tsuda T, Mino Y. A study on a reduction in visits to physicians after introduction of 30% co-payments in the employee health insurance in Japan. Ind Health 2004; 42: 50-56.
54. Treatment guide for diabetes. Tokyo, Japan: Japan Diabetes Society, 2007.
55. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31(Suppl 1): S12-S54.
56. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
57. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, Belgium: International Diabetes Federation, 2005.
58. International Diabetes Federation. Guideline for Management of Postmeal Glucose. Brussels, Belgium: International Diabetes Federation, 2007.
59. Fujisawa T, Ikegami H, Nojima K, et al. Present state of diabetes management in the elderly, Japan. Diabetes Res Clin Pract 2007; 77(Suppl 1): S82-S86.
60. Nakano T. Guideline for the treatment of the elderly with diabetes mellitus [Japanese]. Nippon Rinsho 2006; 64: 64-69.
61. British National Formulary, 55th edn. London: BMJ Group, 2008.
62. Red Book. Pharmacy's fundamental reference. Montvale, NJ: Thomson, 2006.
63. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan - a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
64. Arai K, Hirao K, Matsuba I, et al. The status of glycemic control by general practitioners and specialists for diabetes in Japan: A cross-sectional survey of 15,652 patients with diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 397-401.
65. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 2007; 29: 316-325.
66. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
67. Wens J, Van Casteren V, Vermeire E, Van Royen P, Pas L, Denekens J. Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices. Eur J Epidemiol 2001; 17: 743-750.
68. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
69. Nitiyanant W, Tandhanand S, Mahtab H, et al. The Diabcare-Asia 1998 study - outcomes on control and complications in type 1 and type 2 diabetic patients. Curr Med Res Opin 2002; 18: 317-327.
70. Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006; 28: 388-395.
71. Eppens MC, Craig ME, Jones TW, Silink M, Ong S, Ping YJ. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care and complications. Curr Med Res Opin 2006; 22: 1013-1020.
72. Kanatsuka A, Kawai K, Hirao K,Oishi M, Takagi H, Kobayashi M. Actual usage and clinical effectiveness of insulin preparations in patients with Type 1 diabetes mellitus in Japan: CoDiC-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diabetes Res Clin Pract 2006; 72: 277-283.
73. Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care 2006; 29: 1249-1255.
74. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000; 48: 201-210.
75. Hisashige A, Katayama T, Mikasa H. Costs and effectiveness of intensive insulin therapy for type 2 diabetes. Value in Health 2001; 4: 113.